imiquimod has been researched along with bay 11-7082 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altavilla, D; Anastasi, GP; Arcoraci, V; Bitto, A; Cutroneo, G; Ettari, R; Irrera, N; Lentini, M; Minutoli, L; Pallio, G; Pizzino, G; Scuruchi, M; Squadrito, F; Vaccaro, M | 1 |
1 other study(ies) available for imiquimod and bay 11-7082
Article | Year |
---|---|
BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis.
Topics: Aminoquinolines; Animals; Apoptosis; Cytokines; Dermatologic Agents; Drug Eruptions; Drug Evaluation, Preclinical; Imiquimod; Inflammasomes; Male; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; RNA, Messenger; STAT3 Transcription Factor; Sulfones | 2017 |